With Takeda’s US$62 billion acquisition of Shire in 2018, the Japanese firm scored a spot as a top 10 pharmaceutical firm. But well before the deal was even on the radar, President of R&D Andy Plump and CEO Christophe Weber were already working to transform the company. Once a small-molecule specialist, it is now embracing new modalities to be better positioned to follow the biology of disease. Once internally focused, it is now partnering whenever possible both to bring compelling new projects in and to let promising assets out. And Plump, now celebrating 5 years at the firm, is ready to showcase Takeda’s new look. He spoke with Asher Mullard about Takeda’s plans to leapfrog competitors in immuno-oncology, cellular therapy, rare diseases, gene therapy and more.

中文翻译：

---

安迪（Andy Plump）。

随着武田于2018年以620亿美元收购夏尔（Shire），这家日本公司名列前十名制药公司之列。但是，在交易尚未敲定之前，R＆D总裁Andy Plump和CEO Christophe Weber就已经在努力改造公司。曾经是小分子专家，现在正在采用新的方法以更好地适应疾病的生物学。一旦内部集中精力，它现在就在可能的情况下进行合作，以引入引人入胜的新项目并释放有希望的资产。现在已经在公司庆祝成立5周年的Plump准备展示武田的新面貌。他与Asher Mullard谈了Takeda的计划，该计划在免疫肿瘤学，细胞疗法，罕见疾病，基因疗法等方面超越竞争对手。